Clinical OMICs - Issue 5 - (Page 27)
CANCER AVATARS (continued from p. 7)
sensitivity of patient-derived cancer
cells." The researchers explained that
they began by probing the results
from a recent hypothesis-independent, empirical study by Garnett and
co-workers that analyzed the sensitivity of hundreds of profiled cancer
cell lines to 130 different anticancer
agents. They then used the tumor
model to predict the sensitivity of
patient-derived GBM cell lines to different targeted therapeutic agents.
"Among the drug-mutation associations reported in the Garnett
study, our in silico model accurately
predicted ~85% of the associations,"
wrote the authors. "While testing the
model in a prospective manner using
simulations of patient-derived GBM
cell lines, we compared our simulation predictions with experimental
data using the same cells in vitro. This
analysis yielded a ~75% agreement of
in silico drug sensitivity with in vitro
experimental findings."
"Genomics tells us that cancers are
a lot like snowflakes. No two cancers
are alike so it does not make sense
to give all patients the same drugs.
This is the idea behind personalizing
therapies for cancer," said lead author
Sandeep Pingle, M.D., Ph.D., a project
scientist in the laboratory of Santosh
Kesari, M.D., Ph.D., chief of the division of Neuro-Oncology, professor
in the department of neurosciences,
director of Neuro-Oncology at UC San
Diego Moores Cancer Center and the
study's senior author.
"With the virtual cell model, we can
take into account all the complexity
of cellular processes to predict which
drugs will be the most effective
against a particular tumor based on
its genomic profile," Dr. Pingle added.
"This is a first step toward personalized medicine."
In addition to being an e-publication, Clinical OMICs is a website.
www.clinicalomics.com is updated
frequently with information about
relevant scientific advances, novel
tests, new guidelines, and critical
ethical and reimbursement issues.
You can access the current as well
as past issues of Clinical OMICs in
the archives tab. Check it out daily!
85% of all U.S. cancer
patients are initially diagnosed
in community hospitals.
Expand Dx™ brings personalized
treatment to community hospitals.
Expand Dx™ is designed to enhance and expand community
hospitals offerings in cancer diagnostics and personalized cancer
treatment by introducing new methodologies and testing. This program
works to build on the laboratories' capabilities to increase efficiency
and to help them thrive in today's evolving market.
Learn more at www.cancergenetics.com
www.clinicalomics.com
June 12, 2014 Clinical OMICs
27
http://www.clinicalomics.com
http://www.cancergenetics.com/laboratory-services/cgi-expand-dx/
http://ir.cancergenetics.com/
https://www.facebook.com/CancerGenetics
https://twitter.com/Cancer_Genetics
https://www.linkedin.com/company/cancer-genetics-inc.
https://www.pinterest.com/cancergenetics/
http://www.cancergenetics.com
http://www.clinicalomics.com
Table of Contents for the Digital Edition of Clinical OMICs - Issue 5
Contents
Clinical OMICs - Issue 5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com